Natural Killer Cell Lymphomas Market Make intelligent selections with strategic marketing research reports, current trends, size, shares and growth opportunities in your market.
Albany, NY -- (SBWIRE) -- 06/15/2016 -- Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner. There are two types of lymphomas- Hodgkin's and non-Hodgkin's lymphoma, out of which non-Hodgkin's lymphoma is more common. Natural killer cell (NK) lymphoma is a type of non-Hodgkin's lymphoma. There are three types of NK cell lymphomas namely, extranodal, nasal type and aggressive NK cell lymphoma. Extranodal lymphomas occur in organs other than lymph nodes, hence called as extranodal lymphomas. Nasal type of NK cell lymphomas usually affects nasal areas and paranasal sinuses. Aggressive form of the lymphoma is a very fast growing cancer, because of which prognosis is difficult to study. NK cell lymphomas are also shown to be associated with Epstein Barr Virus (EBV).
Download Natural Killer Cell Lymphomas Report Brochure:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2361
Research and development activities has been impairedbecause of unpredictable prognosis and rare prevalence. Currently Cytoxan (cyclophosphamide), Procytox (cyclophosphamide), Adriamycin(doxorubicin), Oncovin(vincristine), Deltasone (prednisone) are widely used in chemotherapy. While radiation therapy is also practiced for treating the cancer. Various research institutes and corporates are also trying to discover new means to treat the cancer. These include Kirin Holdings Company, Mundipharma International Limited, Fred Hutchinson Cancer Research Center, Sun Yat-sen University, Seoul National University Hospital, University of Minnesota, Zhengzhou University, and M.D. Anderson Cancer Center. Study conducted by Zhengzhou University is currently under Phase IV trial which focuses in evaluation of gemcitabine, pegaspargase, cisplatin, and dexamethasone for chemotherapy.
A study published in Journal of Rare Diseases in 2013, have shown that NK cell lymphomas are common in Asia, Latin America and Central America as compared to North America and Europe. As the prevalence is higher in developing economies, cost of the treatment will be a major barrier for market growth. But a strong pipeline and rising incidences of cancer is expected to support the market in the future.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
Browse Full Report:http://www.transparencymarketresearch.com/natural-killer-cell-lymphomas.html
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453